2/24
07:23 am
fhtx
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
2/24
07:00 am
fhtx
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Low
Report
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
2/23
07:00 am
fhtx
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Low
Report
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
2/17
08:10 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Jefferies Financial Group Inc..
2/3
07:00 am
fhtx
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Low
Report
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
1/13
04:05 pm
fhtx
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Medium
Report
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
1/9
10:20 pm
fhtx
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
High
Report
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
12/20
01:30 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
High
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
12/19
05:58 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
12/18
07:11 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
High
Report
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/6
01:36 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was downgraded by analysts at
Wall St
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was downgraded by analysts at
Wall St